Dostarlimab-gxly: Revision history

25 April 2025

• curprev 13:4113:41, 25 April 2025 Parth Vikram Singh talk contribs 96,220 bytes +3,864 No edit summary
• curprev 13:1913:19, 25 April 2025 Parth Vikram Singh talk contribs 92,356 bytes +216 No edit summary
• curprev 11:3011:30, 25 April 2025 Parth Vikram Singh talk contribs 92,140 bytes +3,225 No edit summary
• curprev 11:2311:23, 25 April 2025 Parth Vikram Singh talk contribs 88,915 bytes +49,694 No edit summary
• curprev 10:5110:51, 25 April 2025 Parth Vikram Singh talk contribs 39,221 bytes +21,391 No edit summary
• curprev 07:2507:25, 25 April 2025 Parth Vikram Singh talk contribs 17,830 bytes +51 No edit summary

24 April 2025

• curprev 11:5311:53, 24 April 2025 Parth Vikram Singh talk contribs 17,779 bytes +17,779 Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=dostarlimab-gxly |aOrAn=a |drugClass=death receptor-1 (PD-1)–blocking antibody |indicationType=treatment |indication=*adult patients with primary advanced or recurrent endometrial cancer (EC). *adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any settin..."